First-in-man implantation of the Tricento transcatheter heart valve for the treatment of severe tricuspid regurgitation
Authors:
- Bart De BoeckBBBart De Boeck
- Miriam BrinkertMBMiriam Brinkert
- Ralf BuhmannRBRalf Buhmann
- Matthias BossardMBMatthias Bossard
- Richard KobzaRKRichard Kobza
- Florim CuculiFCFlorim Cuculi
- 1 September 2018
- journal article
- editorial
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 14 (7) , 758-761
Abstract
Here we describe the first implantation of the novel bicavally anchored Tricento transcatheter heart valve via the transvenous transfemoral access in a 74-year-old woman with severe tricuspid regurgitation and holosystolic hepatic vein backflow. Following successful implantation, caval vein regurgitant volume was reduced leading to symptomatic and clinical improvement at three-month follow-up. The Tricento device represents a promising, novel therapeutic option for patients with severe tricuspid regurgitation who are not candidates for open heart surgery.Keywords
This publication has 4 references indexed in Scilit:
- Diagnosis and treatment of tricuspid valve disease: current and future perspectivesThe Lancet, 2016
- Transcatheter interventions for tricuspid regurgitation - heterotopic technology: TricValveEuroIntervention, 2016
- The Growing Clinical Importance of Secondary Tricuspid RegurgitationJACC, 2012
- Impact of tricuspid regurgitation on long-term survivalJACC, 2004